EMA Authorised: Jyseleca (filgotinib maleate) — Alfasigma S.p.A.

View source ↗

Summary

EMA authorised Jyseleca (filgotinib maleate) for rheumatoid arthritis; decision date 02/06/2025; MAH is Alfasigma S.p.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Jyseleca (Filgotinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: Alfasigma S.p.A.. Decision date: 02/06/2025